An interventional study of transcranial Temporal Interference Stimulation in Autism Spectrum Disorder, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Autism Spectrum Disorder with a site in China — 37 open to participants now, 38 under way, none of them phase 3. Autism Spectrum Disorder · China.
Among the 86 studies in Autism Spectrum Disorder with a site in China, this one is the 60th largest by planned enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2026, is one of 50 with no phase, reaches primary completion later than 15 of the 37 other live ones, and was the 83rd registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →37 of the 86 studies in Autism Spectrum Disorder with a site in China are open now. Recruiting first, the newest first:
Sun Fei · Sites in China
Ages 2–12
Shenzhen Children's Hospital · Sites in China
Ages 3–16
Peking University · Sites in China
Ages 3–6
Dongfang People's Hospital · Sites in China
Ages 3–7
Chen QiYi · Sites in China
Ages 3+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 4 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 1
First in 2014; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 96 across the 63 interventional studies, 130 across the 23 observational. Of the 38 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 86 have an industry lead sponsor. The 10 most frequent:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine has 6 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
15 of the studies in Autism Spectrum Disorder with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07532395Peking UniversityFMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder | 2026-11-24 |
| NCT07509879Qilu Hospital of Shandong UniversityResearch on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder | 2026-12-01 |
| NCT05901558Children's Hospital of Fudan UniversityStrategies for Toddler ASD With Remote-therapy (STAR) Model for ASD | 2026-12-30 |
| NCT07381374Shenzhen Children's HospitalFecal Microbiota Transplantation in Children With ASD | 2026-12-31 |
| NCT06950437Beijing Changping Tianhe Research Institute of Brain SciencepBFS Guided aiTBS Over Language Network for ASD Child | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 86 studies in Autism Spectrum Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this single-blinded, randomized controlled trial is to assess the safety, tolerability, and feasibility of tTIS for children with ASD. The main question it aims to answer is:
- Is tTIS safe, tolerable, and feasible for use for children with autism spectrum disorder?
Researchers will compare tTIS group with control group to explore the safety and feasibility of the transcranial electrical stimulation for children with autism.
Participants will:
From baseline to 4 weeks after intervention completion, subjects will be followed up regarding clinical symptoms and adverse events:
This research is a 5-week single-blinded, randomized controlled trial, planning to enroll 16 ASD children aged 4-10 with a full-scale intelligence quotient (FSIQ) of 50 or above. Children who satisfy all inclusion criteria without meeting any exclusion criteria, may be enrolled after their legal guardians provided the written informed consent.
Eligible subjects will be randomly divided into two groups: tTIS group and sham group. The tTIS group will undergo 5 days of temporal TI stimulation (1.5mA, 2040/2000Hz, 20min/session, 6 sessions/day); the control group will undergo 5 days of temporal TI stimulation (1.5mA, 2000/2000Hz, 20min/session, 6 sessions/day, without 40Hz envelope compared to tTIS group)
At baseline, subjects will undergo physical measurements, demographic and medical history collection, intelligence test and symptom clinical scale assessments, and resting-state EEG collection. From the start of intervention until 4 weeks after completion, subjects will be followed up regarding clinical symptoms, neuroimaging, and adverse events.
Primary Outcome Measures:
- Safety and feasibility of tTIS, assessed by adverse events, treatment completion rate, adherence to the stimulation protocol and tolerability.
Secondary outcomes:
Exploratory Outcomes:
- resting-state and task-state EEG neuroimaging characteristics before intervention, immediately after the 5-day intervention, and 4 weeks after completion of the 5-day intervention
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive tTIS targeting the anterior middle temporal gyrus, with stimulation frequency of 2040/2000HZ, using battery power supply: voltage 12V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days
Device: transcranial Temporal Interference Stimulation
Receive tTIS targeting the anterior middle temporal gyrus, with stimulation frequency of 2000/2000HZ(without 40Hz envelope compared to tTIS group), using battery power supply: voltage 12V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days
Device: transcranial Temporal Interference Stimulation
Receive tTIS targeting the anterior middle temporal gyrus with stimulation frequency of 2040/2000HZ, using battery power supply: voltage 12V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days.
Completion of the tTIS intervention protocol
The proportion of participants who complete all scheduled tTIS sessions according to the predefined stimulation protocol during the 5-day intervention.
Time frame: During the 5-day intervention
Number of participants with adverse events
The number and proportion of participants who experience adverse events during the study period.
Time frame: From the start of the intervention to 4 weeks after completion of the 5-day intervention.
SRS-2
Change from baseline in SRS-2 score immediately after the 5-day intervention. The SRS-2 is primarily used to assess symptoms associated with ASD. Compared to other autism assessment tools, the SRS-2 stands out for its focus on quantifying the severity of social impairment, with higher scores indicating more autism symptoms and greater social disability.
Time frame: Baseline, after completion of 5-day intervention
Childhood Autism Rating Scale (CARS)
Change in CARS score from baseline to 4 weeks after the 5-day intervention. CARS is a behavior rating scale used to assess the presence and severity of the symptoms associated autism spectrum disorder. The scores of the CARS rate from 15 to 60, and higher scores indicate more severe symptoms. The changes in the CAR scores from baseline to 3 months after the treatment will be analyzed to asses the impact often intervention on participants with ASD.
Time frame: Baseline, 4 weeks after completion of 5-day intervention
Social Responsiveness Scale, Second Edition (SRS-2)
Change in SRS-2 score from baseline to 4 weeks after completion of the 5-day intervention.The SRS-2 is primarily used to assess symptoms associated with ASD. Compared to other autism assessment tools, the SRS-2 stands out for its focus on quantifying the severity of social impairment, with higher scores indicating more autism symptoms and greater social disability.
Time frame: Baseline, 4 weeks after completion of 5-day intervention
Chinese Communicative Development Inventory, CCDI
Change in CCDI score from baseline to 4 weeks after the 5-day intervention.Chinese Communicative Development Inventory(CCDl) is a questionnaire used to measures the language abilities. Higher scores suggest better language level. The changes in the CCDl between baseline and 3 month after treatment will be analyzed.
Time frame: Baseline, 4 weeks after completion of 5-day intervention
Peabody Picture Vocabulory Test, PPVT
Change in PPVT score from baseline to 4 weeks after the 5-day intervention. PPVT as a tool for measuring children's language receptive ability and language comprehension ability.
Time frame: Baseline, 4 weeks after completion of 5-day intervention
Neuropsychological Assessment for Child, NEPSY-II
Change in NEPSY-II score from baseline to 4 weeks after the 5-day intervention. NEPSY-II is a comprehensive neuropsychological measurement tool used for assessing neuro-cognitive functions in children aged 3-16 years. This study primarily evaluates the following aspects: narrative memory assessment, facial memory assessment, theory of mind, word generation, affection recognition.
Time frame: Baseline, 4 weeks after completion of 5-day intervention
Vineland Adaptive Behavior Scales-Third Edition, Vineland-3
Change in VABS-3 score from baseline to 4 weeks after the 5-day intervention. The VABS-3 is used to measure adaptive functioning across domains such as communication,daily living skills, socialization, and motor skills. Changes in VABs scores from baseline to 3 months post-treatment will be analyzed to assess the intervention's impact on adaptive behaviors in children with ASD.
Time frame: Baseline, 4 weeks after completion of 5-day intervention
Clinical Global Impression Scale (CGI)
The Clinical Global Impressions (CGI) scale is used to assess both the severity of illness and the global improvement of participants undergoing intervention.
Time frame: after completion of 5-day intervention, four weeks after completion of 5-day intervention
Multilingual Assessment Instrument for Narratives (MAIN)
Change in MAIN score from baseline to 4 weeks after the 5-day intervention. MAIN assess narrative comprehension and production skills of children who exhibited a certain level of expressive ability (at least can use flexible phrases). In this test, children tell or retell the stories and answer some questions, with assessors evaluating performance. Higher scores suggest better language level.
Time frame: Baseline, 4 weeks after completion of 5-day intervention
Change from baseline in alpha-band EEG power
Change in alpha-band EEG power from baseline to immediately after completion of the 5-day intervention and to 4 weeks after completion of the 5-day intervention.
Time frame: Baseline, immediately after completion of the 5-day intervention, and 4 weeks after completion of the 5-day intervention.
Change from baseline in theta-band EEG power
Change in theta-band EEG power from baseline to immediately after completion of the 5-day intervention and to 4 weeks after completion of the 5-day intervention.
Time frame: Baseline, immediately after completion of the 5-day intervention, and 4 weeks after completion of the 5-day intervention.
Change from baseline in inter-trial phase coherence in the alpha band
Change in alpha-band inter-trial phase coherence from baseline to immediately after completion of the 5-day intervention and to 4 weeks after completion of the 5-day intervention.
Time frame: Baseline, immediately after completion of the 5-day intervention, and 4 weeks after completion of the 5-day intervention.
Change from baseline in inter-trial phase coherence in the theta band
Change in theta-band inter-trial phase coherence from baseline to immediately after completion of the 5-day intervention and to 4 weeks after completion of the 5-day intervention.
Time frame: Baseline, immediately after completion of the 5-day intervention, and 4 weeks after completion of the 5-day intervention.
Plan to share: No — The study Protocol, statistical Analysis plan, informed Consent Form, and other relevant documents will be available under reasonable and ethically approved request to the corresponding authors.
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Sep 2026, 4 months later.
Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 4 months is below that.
Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine →